Amsterdam-based Mylan is facing large criticism for the soaring price of EpiPens, which has increased 400 percent since 2007. Prior to his statement, Sen. Manchin refrained from joining his congressional peers in scrutinizing the drug company’s pricing practices.
“I am aware of the questions my colleagues and many parents are asking, and frankly, I share their concerns about the skyrocketing prices of prescription drugs,” said Sen. Manchin in a statement. “Today I heard Mylan’s initial response, and I am sure Mylan will have a more comprehensive and formal response to those questions.”
On Thursday, Mylan responded to public scrutiny by vowing to expand access and increase benefits for its discount programs to help consumers pay less for EpiPens. While the drugmaker addressed immediate consumer costs, it did not say when it would lower list prices or limit future price increases.
“I look forward to reviewing their response in detail and working with my colleagues and all interested parties to lower the price of prescription drugs and to continue to improve our healthcare system,” said Sen. Manchin.
More articles on supply chain:
11 drugmakers with the highest profit margins
EpiPens no longer free for South Carolina’s largest school district
Medical device, drug recalls soar in Q2
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
